SERPASIL
LOE ApproachingNDAORALELIXIRPriority Review
Approved
Aug 1955
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SERPASIL is an oral elixir small-molecule NDA approved in 1955 by Novartis with unknown mechanism of action and indication profile. The drug's exact therapeutic mechanism and patient population cannot be determined from available data.
LOE Approaching
LOE-approaching status suggests small, defensive commercial team focused on market-share protection rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings and LOE-approaching lifecycle indicate minimal career growth or mobility potential on SERPASIL. Roles available would focus on defensive market management and transition planning rather than innovation or commercial expansion.
Brand ManagerField Sales Representative
Worked on SERPASIL at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.